Research article · 1 Jan 2026
Conference abstractPublished 11 Dec 2018
NASH: The increasing trend among the causes of liver cirrhosis
Sisli Florence Nightingale Hospital, Liver Transplantation Unit, Turkey
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
While the global prevalence of liver cirrhosis is not exactly known, the prevalence in the United States is found to be in 0.15% to 0.27% of the population. Approximately 25% of the population of countries such as England, France, Italy, Spain, and Finland is categorized as obese, and people diagnosed with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD), as well as other diseases resulting from metabolic syndrome, are increasing in frequency with time. Tento- 15% of NAFLD patients develop inflammation and fibrosis, which may eventually progress to cirrhosis and hepatocellular carcinoma (HCC). Liver cirrhosis is an important cause of morbidity and mortality in the United States. The curative treatment for liver cirrhosis is liver transplantation. Since 2004, our center has seen an increase in the proportion of non-alcoholic steatohepatitis(NASH)-related liver cirrhosis transplant recipients compared to patients with etiological causes. This implies an increase in the incidence of NASH and NASH-related diseases, including HCC in our population. While in 2009 NASHrelated liver cirrhosis patients comprised 4% of the total transplant recipients at our center, in 2017 this rate has risen up to 20%. Together with this 5-fold increase, the patients with other primary etiologies of liver cirrhosis, such as hepatitis B, C, and autoimmune hepatitis, have been found to have relatively high HOMA-IR index values, showing the presence of a metabolic disorder in these patients. At the same time, the mean average BMI of the transplant patients has increased over the years. Unfavorable developments in modern nutrition are thought to play a role in the impairment of normal metabolism and deterioration of condition in such patients. Independently of the etiology, detection and prevention of underlying metabolic disorders are important in end-stage liver cirrhosis patients.
Subjects
Gastroenterology & HepatologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Gastrointestinal & Digestive System.
Case report · 11 Nov 2025
Bitter Guard: A Gut Wrenching Surprise
Research article · 18 Jun 2025
Ursodeoxycholic Acid Treatment of LPAC Presenting as Post Cholecystectomy Pain: Rationale and Design of a Randomised Trial
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Gastrointestinal & Digestive System
- SubjectGastroenterology & Hepatology
- BylineArticles whose byline prints “Ayfer Serin”